C. Monneret and R. A. Jacquesy, L'épigénétique : enjeux scientifiques, éthiques et sociétaux, L'Act. Chim, vol.407, p.6, 2016.

C. H. Arrowsmith, C. Bountra, P. V. Fish, K. Lee, and M. Schapira, Epigenetic protein families: a new frontier for drug discovery, Nat. Rev. Drug Discov, vol.11, p.384, 2012.

M. Duvic and J. Vu, Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma, Expert Opin. Investig. Drugs, vol.16, p.1111, 2007.

C. Grant, Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors, Expert Rev. Anticancer Ther, vol.10, p.997, 2010.

R. Poole, Belinostat: first global approval, Drugs, vol.74, p.1543, 2014.

M. P. Fenichel, FDA approves new agent for multiple myeloma, J. Natl. Cancer Inst, p.165, 2015.

D. Lowe, China's first homegrown pharma, Seeking Alpha ?, 2015.

E. Bahhaj, F. Dekker, F. J. Martinet, N. Bertrand, and P. , Delivery of epidrugs, Drug Discov. Today, vol.19, p.1337, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01201998

E. A. Mohamed, Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine, J. Pharm. Sci, vol.101, p.3787, 2012.

H. Maeda, Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity, Adv. Drug Deliv. Rev, vol.91, p.3, 2015.

R. Delatouche, P. Bertrand, F. Collette, V. Héroguez, F. Gueugnon et al., Nanovecteurs ou particules et leur utilisation comme médicament et/ou agent de diagnostic, FR20110055761, WO2012FR51498, US2014219925 A1

R. Delatouche, I. Denis, M. Grinda, F. El-bahhaj, E. Baucher et al., Design of pH responsive clickable prodrugs applied to histone deacetylases inhibitors: a new strategy for anticancer therapy, Eur. J. Pharm. Biopharm, vol.85, p.862, 2013.

F. Collette, R. Delatouche, C. Blanquart, F. Gueugnon, M. Grégoire et al., An easy and effective method to produce functionalized particles for cellular uptake, J. Polym. Sci. Part A: Polym. Chem, vol.51, p.176, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00918361

F. Gueugnon, I. Denis, D. Pouliquen, F. Collette, R. Delatouche et al., Nanoparticles produced by ring-opening metathesis polymerization using norbornenyl-poly(ethylene oxide) as a ligand-free generic platform for highly selective in vivo tumor targeting, Biomacromolecules, vol.14, p.2396, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00931576

I. Denis, F. El-bahhaj, F. Collette, R. Delatouche, F. Gueugnon et al., Histone deacetylase inhibitor-polymer conjugate nanoparticles for acid-responsive drug delivery, Eur. J. Med. Chem, vol.95, p.369, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01368838

I. Denis, F. El-bahhaj, F. Collette, R. Delatouche, F. Gueugnon et al., Vorinostat-polymer conjugate nanoparticles for acid-responsive delivery and passive tumor targeting, Biomacromolecules, vol.15, p.4534, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01369441

C. Charrier, J. Clarhaut, J. P. Gesson, G. Estiu, O. Wiest et al., Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression, J. Med. Chem, vol.52, p.3112, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00438795

C. Blanquart, M. François, C. Charrier, P. Bertrand, and M. Grégoire, Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds, Current Cancer Drug Targets, vol.11, p.919, 2011.

F. Gueugnon, P. F. Cartron, C. Charrier, P. Bertrand, J. F. Fonteneau et al., New histone deacetylases inhibitors improve cisplatin antitumor properties against thoracic cancer cells, Oncotarget, vol.5, p.4504, 2014.

E. Bahhaj, F. Denis, I. Pichavant, L. Delatouche, R. Collette et al., Histone deacetylase inhibitors delivery using nanoparticles with intrinsic passive tumor targeting properties for tumor therapy, vol.6, p.795, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01299450

, Activité antitumorale des NP 23. Quatre groupes (G1-G4) de souris C57Bl6 portant des tumeurs AK7 orthotopiques ont été traitées par injection intrapéritonéale de décitabine (4 ?g/g) aux jours 7 et 9, suivie d'injection intraveineuse de NP 21, vol.9

G. Le-groupe, Représentation du poids des tumeurs à la fin du traitement. B-D) Coupes histologiques après coloration HES représentatives de pancréas du groupe contrôle G1 (B)

, Les flèches indiquent les zones d'invasion du pancréas par les cellules tumorales. ns : non significatif

*. *p-<-0, ) valerie.heroguez@enscbp.fr (2) christophe.blanquart@inserm.fr (3) philippe.bertrand@univ-poitiers, p.1